Luxembourg’s space BioTech Exobiosphere secures €1 million to find “cures from space”
Exobiosphere, the Luxembourg-based space BioTech startup working on drug discovery and biomedical research in microgravity, has been awarded €1 million in non-dilutive funding through Luxembourg’s Jeune Entreprise Innovante (JEI) aid scheme. The grant, administered by the Ministry of the Economy, will go toward the company’s commercial expansion, operations, and the scale-up of its orbital…
Luxembourg-based space BioTech startup Exobiosphere has secured €1 million in non-dilutive funding through the Luxembourg innovation scheme Jeune Entreprise Innovante (JEI) to advance its commercial activities. The grant, administered by the Ministry of the Economy, will support the company's orbital high-throughput screening platform and its expansion into new markets.
Founded in 2024, Exobiosphere aims to develop the world's first standardised space-based high-throughput testing platform, the Orbital High-Throughput Screening (OHTS) system, which can run over 2,000 simultaneous automated experiments per mission in microgravity. The company's CEO, Kyle Acierno, expressed gratitude for the support from Luxembourg's innovation ecosystem and the Ministry of Economy, stating that the funding will enable the company to expand its commercial activities, strengthen its team, and bring its technology to pharmaceutical and biotech partners worldwide.
Brief written by urgent.news from EU-Startups's own syndicated text. Machine-written — it may contain errors, so check the original before relying on it.
